| Janssen-Cilag AG - Xeplion 150 mg, Depot-Injektionssuspension in einer Fertigspritze |
| 60466 | | 05 | | Xeplion 150 mg | | Depot-Injektionssuspension in einer Fertigspritze | | N05AX13 | | Paliperidone | | 15.12.2010 | | |
|
| Composition |
| paliperidonum 150 mg ut paliperidoni palmitas 234 mg, polysorbatum 20, macrogolum 4000, acidum citricum monohydricum, dinatrii phosphas, natrii dihydrogenophosphas monohydricus, natrii hydroxidum, aqua ad iniectabile ad suspensionem pro 1.5 ml corresp. natrium 5.503 mg. |
| Packungsbestandteile |
| Retardsuspension zur intramuskulären Injektion | | | | | | | | Active Agent | Dose |
|---|
| Paliperidonum | 150 mg |
| | BAG: Active Agent | Dose |
|---|
| Paliperidonum | 150 mg |
| | | | Inactive agents | Dose |
|---|
| Citric Acid Monohydrate | | | Disodium Phosphate | | | Macrogol | 4000 | | Sodium Dihydrogenophosphate Monohydrate | | | Sodium Hydroxide | | | Polysorbatum 20 | |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 005 | syringe(s) | 435.39 | 477.85 | B | SL | Yes |
|
